↓ Skip to main content

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia

Overview of attention for article published in Frontiers in oncology, February 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
1 news outlet

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
Published in
Frontiers in oncology, February 2021
DOI 10.3389/fonc.2021.637951
Pubmed ID
Authors

Benoît Brethon, Elodie Lainey, Aurélie Caye-Eude, Audrey Grain, Odile Fenneteau, Karima Yakouben, Julie Roupret-Serzec, Lou Le Mouel, Hélène Cavé, André Baruchel

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 9%
Professor 1 9%
Student > Ph. D. Student 1 9%
Student > Doctoral Student 1 9%
Student > Master 1 9%
Other 0 0%
Unknown 6 55%
Readers by discipline Count As %
Unspecified 1 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Immunology and Microbiology 1 9%
Medicine and Dentistry 1 9%
Engineering 1 9%
Other 0 0%
Unknown 6 55%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2022.
All research outputs
#4,862,455
of 25,477,125 outputs
Outputs from Frontiers in oncology
#1,704
of 22,568 outputs
Outputs of similar age
#118,261
of 450,654 outputs
Outputs of similar age from Frontiers in oncology
#95
of 946 outputs
Altmetric has tracked 25,477,125 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,568 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,654 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 946 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.